×

Sign In

Search
Home

Glenmark Pharma jumps on unit’s cancer licensing deal with AbbVie

By Thomson Reuters Jul 10, 2025 | 10:55 PM

(Reuters) -Shares of Glenmark Pharmaceuticals jumped 10% in early trade on Friday, a day after a unit of the Indian drugmaker signed an exclusive licensing deal with U.S. peer AbbVie for its cancer treatment.

(Reporting by Hritam Mukherjee in Bengaluru; Editing by Sonia Cheema)

White House preparing order that could limit military contractor compensation, Punchbowl reports

Belarusian president calls for fast action on Ukraine war while US is engaged

Australia's Star Entertainment names Bruce Mathieson Jr as new CEO

Some Trump officials cast doubts on Hassett for Fed chair, Politico reports

Former Michigan coach Jim Harbaugh reached out to Sherrone Moore: 'It's a tragedy'

AI romance blooms as Japan woman weds virtual partner of her dreams

Privacy Policy
Terms Of Service

Copyright © 2025. All Rights Reserved.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at 715-842-1672.